Basking Biosciences Announces Close of $55 Million Financing
Basking Biosciences Presents Novel Reversible RNA-aptamer Thrombolytic at Locus Walk RNA Innovation Conference
Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023
Basking Biosciences to Present Clinical Trial Results on First Reversible Thrombolytic Agent at American Heart Association International Stroke Conference 2023